Please use this identifier to cite or link to this item: http://doi.org/10.25358/openscience-7952
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDeng, Shiwei-
dc.contributor.authorYan, Tiandong-
dc.contributor.authorJendrny, Cathleen-
dc.contributor.authorNemecek, Andrea-
dc.contributor.authorVincetic, Mladen-
dc.contributor.authorGödtel-Armbrust, Ute-
dc.contributor.authorWojnowski, Leszek-
dc.date.accessioned2022-10-12T10:18:30Z-
dc.date.available2022-10-12T10:18:30Z-
dc.date.issued2014
dc.identifier.urihttps://openscience.ub.uni-mainz.de/handle/20.500.12030/7967-
dc.description.abstractBACKGROUND: The bisdioxopiperazine dexrazoxane (DRZ) prevents anthracycline-induced heart failure, but its clinical use is limited by uncertain cardioprotective mechanism and by concerns of interference with cancer response to anthracyclines and of long-term safety. METHODS: We investigated the effects of DRZ on the stability of topoisomerases IIalpha (TOP2A) and IIbeta (TOP2B) and on the DNA damage generated by poisoning these enzymes by the anthracycline doxorubicin (DOX). RESULTS: DRZ given i.p. transiently depleted in mice the predominant cardiac isoform Top2b. The depletion was also seen in H9C2 cardiomyocytes and it was attenuated by mutating the bisdioxopiperazine binding site of TOP2B. Consistently, the accumulation of DOX-induced DNA double strand breaks (DSB) by wild-type, although not by mutant TOP2B, was reduced by DRZ. In contrast, the DRZ analogue ICRF-161, which is capable of iron chelation but not of TOP2B binding and cardiac protection, did not deplete TOP2B and did not prevent the accumulation of DOX-induced DSB. TOP2A, re-expressed in cultured cardiomyocytes by fresh serum, was depleted by DRZ along with TOP2B. DRZ depleted TOP2A also from fibrosarcoma-derived cells, but not from lung cancer-derived and human embryo-derived cells. DRZ-mediated TOP2A depletion reduced the accumulation of DOX-induced DSB. CONCLUSIONS: Taken together, our data support a model of anthracycline-induced heart failure caused by TOP2B-mediated DSB and of its prevention by DRZ via TOP2B degradation rather than via iron chelation. The depletion of TOP2B and TOP2A suggests an explanation for the reported DRZ interference with cancer response to anthracyclines and for DRZ side-effects.en_GB
dc.description.sponsorshipDFG, Open Access-Publizieren Universität Mainz / Universitätsmedizinde
dc.language.isoengde
dc.rightsCC BY*
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subject.ddc610 Medizinde_DE
dc.subject.ddc610 Medical sciencesen_GB
dc.titleDexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoformsen_GB
dc.typeZeitschriftenaufsatzde
dc.identifier.doihttp://doi.org/10.25358/openscience-7952-
jgu.type.dinitypearticleen_GB
jgu.type.versionPublished versionde
jgu.type.resourceTextde
jgu.organisation.departmentFB 04 Medizinde
jgu.organisation.number2700-
jgu.organisation.nameJohannes Gutenberg-Universität Mainz-
jgu.rights.accessrightsopenAccess-
jgu.journal.titleBMC cancerde
jgu.journal.volume14de
jgu.pages.alternativeArt. 842de
jgu.publisher.year2014-
jgu.publisher.nameBioMed centralde
jgu.publisher.placeLondonde
jgu.publisher.urihttp://dx.doi.org/10.1186/1471-2407-14-842de
jgu.publisher.issn1471-2407de
jgu.organisation.placeMainz-
jgu.identifier.pmid25406834
jgu.subject.ddccode610de
opus.date.modified2018-08-09T08:23:08Z
opus.subject.dfgcode00-000
opus.organisation.stringFB 04: Medizin: Institut für Pharmakologiede_DE
opus.identifier.opusid50524
opus.importsourcepubmed
opus.institute.number0413
opus.metadataonlyfalse
opus.type.contenttypeKeinede_DE
opus.type.contenttypeNoneen_EN
opus.affiliatedWojnowski, Leszek
jgu.publisher.doi10.1186/1471-2407-14-842de
jgu.organisation.rorhttps://ror.org/023b0x485-
Appears in collections:DFG-OA-Publizieren (2012 - 2017)

Files in This Item:
  File Description SizeFormat
Thumbnail
dexrazoxane_may_prevent_doxor-20220925143048362.pdf1.1 MBAdobe PDFView/Open